- Home
- INVA vs IMTX Comparison
INVA vs IMTX Comparison
Compare INVA & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | IMTX |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | INVA | IMTX |
|---|---|---|
| Price | $19.56 | $9.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $36.80 | $19.25 |
| AVG Volume (30 Days) | ★ 630.7K | 367.1K |
| Earning Date | 02-25-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.96 | N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $388,521,000.00 | $99,445,031.00 |
| Revenue This Year | $13.23 | N/A |
| Revenue Next Year | $8.58 | $19.39 |
| P/E Ratio | $12.93 | ★ N/A |
| Revenue Growth | ★ 10.14 | N/A |
| 52 Week Low | $16.52 | $3.30 |
| 52 Week High | $22.76 | $12.41 |
Technical Indicators
Market Signals| Indicator | INVA | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 49.00 |
| Support Level | $19.42 | $9.37 |
| Resistance Level | $19.90 | $10.36 |
| Average True Range (ATR) | 0.42 | 0.47 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 64.42 | 63.79 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.